BVT 2733
BVT 2733 性质
| 沸点 | 636.9±65.0 °C(Predicted) |
|---|---|
| 密度 | 1.427±0.06 g/cm3(Predicted) |
| 储存条件 | 2-8°C |
| 溶解度 | DMSO 中≥42.9 mg/mL；不溶于水；不溶于乙醇 |
| 形态 | 固体 |
| 酸度系数(pKa) | 6.36±0.10(Predicted) |
BVT 2733 用途与合成方法
| Target | Value |
|
11β-HSD1
() |
BVT 2733 (100 μM; 24 hours) co-treatment with PA (100 µM) reduces MCP-1 expression in fully differentiation adipocytes.BVT 2733 (50-100 μM; 24 hours) reduces the inflammation protein levels (MCP-1, IL-6) in medium in J774.1 macrophages by Elisa.
RT-PCR
| Cell Line: | Differentiation adipocytes |
| Concentration: | 100 μM |
| Incubation Time: | 24 hours |
| Result: | Down-regulated MCP-1 mRNA level. |
BVT-2733 (oral administration; 100 mg/kg; twice daily; 2 weeks) attenuates the arthritis severity and anti-CII level and decreases the levels of serum TNF-α, IL-1β, IL-6 and IL-17 in CIA mice.BVT 2733 (oral administration; 100 mg/kg; dosed (09.00 and 17.00 h); last 4 weeks) exhibits decreased body weight and enhanced glucose tolerance and insulin sensitivity when it compares to control mice. It also down-regulated the expression of inflammation-related genes including monocyte chemoattractant protein 1 (MCP-1), tumor necrosis factor alpha (TNF-α) and the number of infiltrated macrophages within the adipose tissue in vivo.
| Animal Model: | Collagen-induced arthritis (CIA) mice |
| Dosage: | 100 mg/kg |
| Administration: | Oral administration; twice daily; 2 weeks |
| Result: | Reduced synovial inflammation and joint destruction. |
| Animal Model: | C57BL/6J mice |
| Dosage: | 100 mg/kg |
| Administration: | Oral administration; dosed (09.00 and 17.00 h); last 4 weeks |
| Result: | Improved metabolic homeostasis and suppressed the inflammation of adipose tissue in diet-induced obese mice. |
BVT 2733 价格(试剂级)
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024-01-16 | S0209 | BVT 2733 | 376640-41-4 | 5mg | 657.46 |
| 2024-01-16 | S0209 | BVT 2733 | 376640-41-4 | 25mg | 2383.47 |
